I. Accepted Diagnostic Techniques

A. Standard Diagnostic Nocturnal Polysomnography (NPSG)
Based on the 1997 American Sleep Disorders Association Indications for Polysomnography Task Force Report 1 :
• Indicated for the diagnosis of possible obstructive sleep apnea (OSA).
• Includes recording and analysis of the following parameters: EEG, electro-oculogram (EOG), electromyogram (EMG), oronasal airflow, chest wall effort, body position, snore microphone, ECG, and oxyhemoglobin saturation. The duration of a diagnostic NPSG is at least 6 h (with the consensus statement CHEST / 115 / 3 / MARCH, 1999 exception of the diagnostic portion of a splitnight study, which is at least 2 h in duration; refer to section IB).
• 6-h minimum duration of a diagnostic NPSG is preferred, which allows for the assessment of variability related to sleep stage and position with respect to the frequency of obstructive respiratory events and the occurrence of other types of nocturnal events such as periodic limb movements.
• Standard diagnostic NPSG may be performed in a health-care facility or in the patient's home with a trained technologist in attendance. The use of unattended, standard diagnostic NPSG in the patient's home is not a validated clinical technique. Diagnostic NPSG must be interpreted by a physician trained in the evaluation and treatment of OSA patients. • Apnea is defined as the cessation of airflow Ն 10 s.
B. Split-Night Study NPSG
• Hypopnea is defined as a recognizable, transient reduction, but not a complete cessation of, breathing Ն 10 s. A Ն 50% decrease in the amplitude of a validated measure of breathing or a Ͻ 50% amplitude reduction that is associated with either an oxygen desaturation of Ն 3% or an arousal must be evident.
• Obstructive apneas and hypopneas are typically distinguished from central events by the detection of respiratory efforts during the event.
• A respiratory effort-related arousal (RERA) is an event characterized by increasing respiratory effort for Ն 10 s leading to an arousal from sleep but which does not fulfill the criteria for a hypopnea or apnea. A RERA is detected with nocturnal esophageal catheter pressure measurement, which demonstrates a pattern of progressive negative esophageal pressures terminated by a change in pressure to a less negative pressure level associated with an arousal. Novel techniques are available that may allow for increased technical ease in the detection of RERAs.
• The RDI is defined as the number of obstructive apneas, hypopneas, and RERAs per hour averaged over the course of at least 2 h of sleep as determined by NPSG.
III. Treatment Criteria
• CPAP treatment is indicated for all OSA patients with an RDI Ն 30 events per hour, regardless of symptoms, based on the increased risk of hypertension evident from the Wisconsin sleep cohort data. 11 • Treatment with CPAP is indicated for patients with an RDI of 5 to 30 events per hour accom-panied by symptoms of excessive daytime sleepiness, 12 impaired cognition, 13,14 mood disorders, 13 insomnia, 15 or documented cardiovascular diseases to include hypertension, 16 ischemic heart disease, 17 or stroke. 18 The use of an RDI of 5 events per hour as the minimal threshold value for CPAP treatment of symptomatic OSA patients is supported by the studies of Redline et al 14 and Engleman et al 19 that demonstrated improvements in symptoms and daytime function.
• Treatment with CPAP is not indicated for asymptomatic patients without cardiovascular diseases who demonstrate mild OSA on diagnostic NPSG.
• Only physicians trained in the evaluation and treatment of OSA patients shall prescribe CPAP for this indication.
IV. CPAP Titration
• On a subsequent night following a diagnostic NPSG or following the diagnostic portion of a split-night study, OSA patients receive CPAP titration to specify the lowest CPAP level, which abolishes obstructive apneas, hypopneas, RERAs, and snoring in all sleep positions and sleep stages. 20 • Minimum parameters to be monitored and analyzed with CPAP titration NPSG include the following: EEG, EOG, EMG, oronasal airflow, chest wall effort, body position, snore microphone, ECG, and oxyhemoglobin saturation. Inclusion of EEG, EOG, and EMG in CPAP titration NPSG parameters allows for detection of arousals and avoids possible undertitration due to otherwise unrecognized episodes of wakefulness and detection of various sleep stages to allow for the optimization of manually specified pressure requirements. 1
V. Bilevel Positive Airway Pressure
• Bilevel positive airway pressure (PAP) allows for independent adjustment of inspiratory and expiratory pressures. A timed, back-up rate capability is not required for OSA treatment.
• A trial of bilevel PAP may be indicated for OSA patients who cannot tolerate CPAP due to persistent massive nasal mask air leakage or discomfort exhaling against positive pressure. 21 • A trial of bilevel PAP may be indicated for OSA patients with concomitant nocturnal breathing disorders to include restrictive thoracic disorders, COPD, and nocturnal hypoventilation. 22 • Although initial acceptance of PAP treatment is increased with the availability of bilevel PAP, 23 it may not be routinely indicated as an alternative to CPAP in OSA patients because there may not be an increase in the hours of use. 24 • An additional NPSG may be required to titrate bilevel PAP if CPAP failure occurs.
VI. Autotitrating PAP
• Autotitrating PAP allows for the titration of CPAP without the immediate involvement of a technologist.
• Recent studies suggest that some autotitrating PAP systems are effective in determining the optimal CPAP setting for most OSA patients. 25 • Treatment with autotitrating PAP systems in some studies shows slight increases in adherence as compared with CPAP. 26, 27 • An additional NPSG may be required to titrate CPAP if autotitrating PAP treatment failure occurs.
VII. Repeat NPSG
• Indications for repeat NPSG are persistence of symptoms despite adherence to PAP treatment and assessment of treatment response to upper airway surgical procedures, oral appliances, or significant sustained weight change (Ͼ 15%). 1 
VIII. Adherence to PAP Treatment
• Efforts directed at OSA patient education are warranted for at least the first month of PAP treatment to promote effective long-term adherence with treatment. 21, 28 This education may be provided by physicians, specially trained technologists, or nurses.
• To enhance and ensure PAP adherence and equipment maintenance, follow-up with a physician or a designated surrogate should occur at least once after the initiation of PAP treatment, and thereafter on at least a yearly basis. 21 • Adjustments or changes in the PAP-patient interface are not uncommon and may be indicated, due to difficulties with mask fit leading to skin abrasion, massive air leak, or to mask, tubing, or rebreathing valve breakage. 29 • Adequate adherence to PAP is defined as Ͼ 4.5 h of PAP use per night on a routine basis. 23 • Maximal improvement in neurocognitive symptoms can require as long as 2 months of PAP treatment. 14, 30 
